Tamura, Kouichi
Ohki, Koji
Kobayashi, Ryu
Uneda, Kazushi
Azushima, Kengo
Ohsawa, Masato
Wakui, Hiromichi
Sakai, Masashi
Tokita, Yasuo
Umemura, Satoshi
Article History
First Online: 4 September 2014
Competing interests
: K Tamura received honoraria, consulting fees or funds from Mochida, Daiichi-Sankyo, Dainippon-Sumitomo, Novartis, Takeda, MSD, Kyowa-hakko Kirin, Shionogi, Boehringer Ingelheim, Astellas, Tanabe Mitsubishi, Pfizer, Chu-gai, AstraZeneca and Sanofi. S Umemura received honoraria, consulting fees or funds from Shionogi, Astellas, Torii, Dainippon-Sumitomo, Boehringer Ingelheim, MSD, Pfizer, Daiichi-Sankyo, Novartis, AstraZeneca, Takeda, Kyowa-hakko Kirin, Kowasoyaku, Acterion, Otsuka, Bayer, Chugai, Mochida, Tanabe Mitsubishi, Teijin, Sanofi and Sanwa-kagaku. The remaining authors declare no conflict of interest.